fda compounding glp-1 enforcement news november 2025 A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio Harvard Business Review | A

In an attempt to compensate for the loss, other pathways are upregulated, e.g., the increased use of ketones produced from fatty acids by astrocytes that are shuttled to neurons

Women in menopause are turning to GLP1 weight-loss drugs

Oral semaglutide showed cardiovascular safety profile, with significant reduced risk of death from cardiovascular events

Tirzepatide 15 mg produced similar weight loss results as bariatric surgery among patients with obesity but had a favorable safety profile, according to a presenter at the ACG Annual Scientific Meeting

We review and include products we think are useful for our community

This kinase is...